(AVAH) Aveanna Healthcare Holdings - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NASDAQ (USA) | Market Cap: 1.596m USD | Total Return: 33.6% in 12m
Avg Turnover: 9.99M
Qual. Beats: 1
Rev. Trend: 96.4%
Qual. Beats: 1
Warnings
Altman Z'' -0.83 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Confidence
Aveanna Healthcare Holdings Inc. (AVAH) is a specialized home care provider focused on pediatric and adult populations across the United States. The company operates through three primary segments: Private Duty Services, Home Health & Hospice, and Medical Solutions. Its business model relies on a decentralized care delivery platform designed to reduce reliance on high-cost institutional settings like hospitals by providing skilled nursing, therapy, and medical supplies directly in the patient’s home.
The pediatric home care sector is characterized by high clinical complexity and long-term patient relationships, often supported by specialized Medicaid programs. Aveanna’s Medical Solutions segment complements its clinical services by managing the logistics of enteral nutrition and respiratory supplies, creating a recurring revenue stream tied to daily patient needs. Investors should examine ValueRay for further data on how these segments perform relative to industry peers.
Headquartered in Atlanta, Georgia, the company integrates clinical nursing with non-clinical support services and school-based care. This diversified approach allows the firm to capture value across the continuum of care, from neonatal transitions to hospice services. The regulatory environment for home health remains a critical factor for the firm, as reimbursement rates are frequently subject to federal and state legislative adjustments.
- Medicaid reimbursement rate updates directly impact Private Duty Services segment margins
- Labor market tightness and caregiver wage inflation pressure operational profitability
- Shift toward home-based care models drives increased patient volume and referrals
- Federal and state regulatory changes influence Home Health and Hospice revenue
- High debt leverage makes earnings sensitive to interest rate fluctuations
| Net Income: 261.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 5.03 > 1.0 |
| NWC/Revenue: 7.33% < 20% (prev 0.92%; Δ 6.41% < -1%) |
| CFO/TA 0.07 > 3% & CFO 138.8m > Net Income 261.5m |
| Net Debt (1.35b) to EBITDA (306.4m): 4.42 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (222.1m) vs 12m ago 7.69% < -2% |
| Gross Margin: 32.67% > 18% (prev 0.32%; Δ 3.24k% > 0.5%) |
| Asset Turnover: 137.0% > 50% (prev 126.0%; Δ 10.92% > 0%) |
| Interest Coverage Ratio: 2.12 > 6 (EBITDA TTM 306.4m / Interest Expense TTM 132.9m) |
| A: 0.09 (Total Current Assets 575.3m - Total Current Liabilities 390.4m) / Total Assets 2.02b |
| B: -0.55 (Retained Earnings -1.12b / Total Assets 2.02b) |
| C: 0.15 (EBIT TTM 281.9m / Avg Total Assets 1.84b) |
| D: -0.63 (Book Value of Equity -1.11b / Total Liabilities 1.78b) |
| Altman-Z'' = -0.83 = CCC |
| DSRI: 0.91 (Receivables 335.6m/305.3m, Revenue 2.52b/2.09b) |
| GMI: 0.98 (GM 32.67% / 32.17%) |
| AQI: 0.96 (AQ_t 0.69 / AQ_t-1 0.72) |
| SGI: 1.20 (Revenue 2.52b / 2.09b) |
| TATA: 0.06 (NI 261.5m - CFO 138.8m) / TA 2.02b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of May 27, 2026, the stock is trading at USD 7.28 with a total of 1,331,668 shares traded.
Over the past week, the price has changed by -5.45%,
over one month by +7.85%,
over three months by +0.83% and
over the past year by +33.58%.
Aveanna Healthcare Holdings has received a consensus analysts rating of 2.88. Therefore, it is recommended to hold AVAH.
- StrongBuy: 1
- Buy: 0
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 10.1 | 38% |
P/E Trailing = 6.0579
P/E Forward = 10.1833
P/S = 0.6329
P/B = 6.6335
Revenue TTM = 2.52b USD
EBIT TTM = 281.9m USD
EBITDA TTM = 306.4m USD
Long Term Debt = 1.28b USD (from longTermDebt, last quarter)
Short Term Debt = 193.7m USD (from shortTermDebt, last quarter)
Debt = 1.54b USD (from shortLongTermDebtTotal, last quarter) + Leases 40.1m
Net Debt = 1.35b USD (calculated: Debt 1.54b - CCE 189.3m)
Enterprise Value = 2.95b USD (1.60b + Debt 1.54b - CCE 189.3m)
Interest Coverage Ratio = 2.12 (Ebit TTM 281.9m / Interest Expense TTM 132.9m)
EV/FCF = 21.59x (Enterprise Value 2.95b / FCF TTM 136.6m)
FCF Yield = 4.63% (FCF TTM 136.6m / Enterprise Value 2.95b)
FCF Margin = 5.42% (FCF TTM 136.6m / Revenue TTM 2.52b)
Net Margin = 10.37% (Net Income TTM 261.5m / Revenue TTM 2.52b)
Gross Margin = 32.67% ((Revenue TTM 2.52b - Cost of Revenue TTM 1.70b) / Revenue TTM)
Gross Margin QoQ = 31.24% (prev 31.79%)
Tobins Q-Ratio = 1.46 (Enterprise Value 2.95b / Total Assets 2.02b)
Interest Expense / Debt = 8.62% (Interest Expense 132.9m / Debt 1.54b)
Taxrate = 7.39% (3.32m / 45.0m)
NOPAT = 261.1m (EBIT 281.9m * (1 - 7.39%))
Current Ratio = 1.47 (Total Current Assets 575.3m / Total Current Liabilities 390.4m)
Debt / Equity = 6.43 (Debt 1.54b / totalStockholderEquity, last quarter 240.1m)
Debt / EBITDA = 4.42 (Net Debt 1.35b / EBITDA 306.4m)
Debt / FCF = 9.90 (Net Debt 1.35b / FCF TTM 136.6m)
Total Stockholder Equity = 108.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.20% (Net Income 261.5m / Total Assets 2.02b)
RoE = 21.37% (Net Income TTM 261.5m / Total Stockholder Equity 1.22b)
RoCE = 11.24% (EBIT 281.9m / Capital Employed (Equity 1.22b + L.T.Debt 1.28b))
RoIC = 15.10% (NOPAT 261.1m / Invested Capital 1.73b)
WACC = 11.50% (E(1.60b)/V(3.14b) * Re(14.91%) + D(1.54b)/V(3.14b) * Rd(8.62%) * (1-Tc(0.07)))
Discount Rate = 14.91% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 84.11 | Cagr: 7.16%
[DCF] Terminal Value 68.47% ; FCFF base≈93.4m ; Y1≈107.1m ; Y5≈157.6m
[DCF] Fair Price = 0.77 (EV 1.52b - Net Debt 1.35b = Equity 167.1m / Shares 217.8m; r=11.50% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.38 | # QB: 1
Revenue Correlation: 96.44 | Revenue CAGR: 11.96% | SUE: 1.97 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+3.94% | Revisions=+33% | Analysts=11
EPS next Quarter (2026-09-30): EPS=0.16 | Chg30d=+0.62% | Revisions=+11% | Analysts=11
EPS current Year (2026-12-31): EPS=0.68 | Chg30d=+9.96% | Revisions=+67% | GrowthEPS=+13.9% | GrowthRev=+6.8%
EPS next Year (2027-12-31): EPS=0.75 | Chg30d=+8.08% | Revisions=+67% | GrowthEPS=+9.2% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +67%